[Possible involvement of GABAB receptors in action of antidepressants].
Antidepressants are divided into several groups such as monoamine oxidase inhibitors, serotonin reuptake inhibitors, noradrenaline reuptake inhibitors and alpha-adrenoceptor antagonists. Antidepressants show, however, a common clinical profile: their clinical actions occur after a chronic treatment. It is, therefore, suggested that antidepressants have a common pharmacological profile. We reviewed possible involvement of gamma-aminobutyric acid (GABA)B receptors in action of antidepressants. Our data in combination with previous ones from other laboratories suggest that antidepressants suppress the activity of presynaptic 5-hydroxytryptamine3 receptors on GABA neurons, resulting in the reduction of GABA release. It is likely that the decrease in GABA release attenuates GABAB receptor-mediated neurotransmission, thereby upregulating GABAB receptors.
Nakagawa
Yutaka
Y
Pharmaceutical Marketing Center, Kyowa Hakko Kogyo Co. Ltd., 1-6-1, Otemachi, Chiyoda-ku, Tokyo, 100-8185 Japan.
Ishima
Tsuyoshi
T
D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D003864:Depression, Chemical; D006801:Humans; D018080:Receptors, GABA-B / Q000378:metabolism* / Q000502:physiology; D011985:Receptors, Serotonin / Q000378:metabolism; D044406:Receptors, Serotonin, 5-HT3; D009435:Synaptic Transmission / Q000187:drug effects; D015854:Up-Regulation; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D000928:Antidepressive Agents; D018080:Receptors, GABA-B; D011985:Receptors, Serotonin; D044406:Receptors, Serotonin, 5-HT3; D005680:gamma-Aminobutyric Acid